Background: The ongoing phase IIb POWER 1 (TMC114-C213) trial is designed to assess efficacy and safety of the protease inhibitor (PI) TMC114 (darunavir) in treatment-experienced HIV-1-infected patients. Design: This randomized, partially blinded, 24-week dose-finding study compared efficacy and safety of four doses of TMC114 plus low-dose ritonavir (TMC114/r) with investigator-selected control PI(s) (CPI[s]). Methods: Patients with one or more primary PI mutation and HIV RNA > 1000 copies/ml received optimized background therapy, plus TMC114/r 400/100 mg once daily, 800/100 mg once daily, 400/100 mg twice daily or 600/100 mg twice daily, or CPI(s). The primary endpoint (intent-to-treat) compared proportions of patients achieving viral load reduction >= 1.0log(10)copies/ml from baseline. Results: In total, 318 patients were treated. Baseline mean viral load was 4.48log(10) copies/ml; median CD4 cell count was 179 cells/mu l. In the CPI arm 62% of patients discontinued (virological failure: 54%); 10% of TMC114/r patients discontinued. More TMC114/r (69-77%) than CPI patients (25%) reached the primary endpoint (P < 0.001); 43-53% of TMC114/r patients and 18% of the CPI arm achieved viral load < 50 copies/ml (P < 0.001). TMC114/r demonstrated greater mean CD4 cell count increases versus CPI(s) (68-124 versus 20cells/mu l; P < 0.05). TMC114/r 600/100 mg twice daily demonstrated the highest virological and immunological responses. Adverse event incidence was similar between treatments; headache and diarrhoea were more common with CPI(s). Conclusions: TMC114/r demonstrated statistically higher 24-week virological response rates and CD4 cell count increases than CPI(s). TMC114/r 600/100 mg twice daily has received regulatory approval in treatment-experienced patients. (c) 2007 Lippincott Williams & Wilkins.
|Anno di pubblicazione:||2007|
|Titolo:||Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1|
|Autore/i:||Katlama C.; Esposito R.; Gatell J.M.; Goffard J.C.; Grinsztejn B.; Pozniak A.; Rockstroh J.; Stoehr A.; Vetter N.; Yeni P.; Parys W.; Vangeneugdenk T.|
|Codice identificativo ISI:||WOS:000244910000001|
|Codice identificativo Scopus:||2-s2.0-33847041109|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris